Cargando…

Carbon Monoxide Diffusing Capacity (DL(CO)) Correlates with CT Morphology after Chemo-Radio-Immunotherapy for Non-Small Cell Lung Cancer Stage III

Introduction: Curatively intended chemo-radio-immunotherapy for non-small cell lung cancer (NSCLC) stage III may lead to post-therapeutic pulmonary function (PF) impairment. We hypothesized that the decrease in global PF corresponds to the increase in tissue density in follow-up CTs. Hence, the stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stana, Markus, Grambozov, Brane, Gaisberger, Christoph, Karner, Josef, Ruznic, Elvis, Berchtold, Johannes, Zellinger, Barbara, Moosbrugger, Raphaela, Studnicka, Michael, Fastner, Gerd, Sedlmayer, Felix, Zehentmayr, Franz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139430/ https://www.ncbi.nlm.nih.gov/pubmed/35626183 http://dx.doi.org/10.3390/diagnostics12051027

Ejemplares similares

Chemo-Radio-Immunotherapy for NSCLC III: ESR/ATS Thresholds for DL(CO) Correlate with Radiation Dosimetry and Pneumonitis Rate
por: Stana, Markus, et al.
Publicado: (2023)

High Dose Thoracic Re-Irradiation and Chemo-Immunotherapy for Centrally Recurrent NSCLC
por: Grambozov, Brane, et al.
Publicado: (2022)

Hsa-miR-3651 could serve as a novel predictor for in-breast recurrence via FRMD3
por: Zellinger, Barbara, et al.
Publicado: (2021)

Impact of reirradiation, chemotherapy, and immunotherapy on survival of patients with recurrent lung cancer: A single‐center retrospective analysis
por: Grambozov, Brane, et al.
Publicado: (2021)

Re-Irradiation for Locally Recurrent Lung Cancer: A Single Center Retrospective Analysis
por: Grambozov, Brane, et al.
Publicado: (2021)

Pulmonary function decreases moderately after accelerated high‐dose irradiation for stage III non‐small cell lung cancer
por: Grambozov, Brane, et al.
Publicado: (2019)

Radiation dose escalation with modified fractionation schedules for locally advanced NSCLC: A systematic review
por: Zehentmayr, Franz, et al.
Publicado: (2020)

Hsa-miR-375/RASD1 Signaling May Predict Local Control in Early Breast Cancer
por: Zellinger, Barbara, et al.
Publicado: (2020)

Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Trospective Comparison Focusing on Pulmonary Toxicity
por: Wass, Romana, et al.
Publicado: (2022)

Survival in early lung cancer patients treated with high dose radiotherapy is independent of pathological confirmation
por: Zehentmayr, Franz, et al.
Publicado: (2019)

First clinical application of image-guided intraoperative electron radiation therapy with real time intraoperative dose calculation in recurrent rectal cancer: technical procedure
por: Roeder, Falk, et al.
Publicado: (2023)

Hsa-miR-375 is a predictor of local control in early stage breast cancer
por: Zehentmayr, Franz, et al.
Publicado: (2016)

Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid)
por: Zehentmayr, Franz, et al.
Publicado: (2015)

Boost IORT in Breast Cancer: Body of Evidence
por: Sedlmayer, Felix, et al.
Publicado: (2014)

Intraoperative radiotherapy (IORT) as boost in breast cancer
por: Sedlmayer, Felix, et al.
Publicado: (2017)

Nonmetastatic pancreatic cancer: Improved survival with chemoradiotherapy > 40 Gy after systemic treatment
por: Bachmayer, Sebastian, et al.
Publicado: (2018)

miR-16-5p Is a Stably-Expressed Housekeeping MicroRNA in Breast Cancer Tissues from Primary Tumors and from Metastatic Sites
por: Rinnerthaler, Gabriel, et al.
Publicado: (2016)

DART-bid (Dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily)–a novel approach for non-resected NSCLC: final results of a prospective study, correlating radiation dose to tumor volume
por: Wurstbauer, Karl, et al.
Publicado: (2013)

DART-bid for loco-regionally advanced NSCLC: Summary of acute and late toxicity with long-term follow-up; experiences with pulmonary dose constraints
por: Wurstbauer, Karl, et al.
Publicado: (2017)

Subjective voice quality, communicative ability and swallowing after definitive radio(chemo)therapy, laryngectomy plus radio(chemo)therapy, or organ conservation surgery plus radio(chemo)therapy for laryngeal and hypopharyngeal cancer
por: Szuecs, Marcella, et al.
Publicado: (2015)

Reply to: The challenge of cardiac dose constraint adaptation to hypofractionated breast radiotherapy in clinical practice
por: Piroth, Marc D., et al.
Publicado: (2021)

The roles of glucose metabolic reprogramming in chemo- and radio-resistance
por: Lin, Jinguan, et al.
Publicado: (2019)

Hypofractionated Whole Breast Irradiation and Boost-IOERT in Early Stage Breast Cancer (HIOB): First Clinical Results of a Prospective Multicenter Trial (NCT01343459)
por: Fastner, Gerd, et al.
Publicado: (2022)

Longitudinal atherosclerotic changes after radio(chemo)therapy of hypopharyngeal carcinoma
por: Simonetto, Cristoforo, et al.
Publicado: (2020)

Radio(chemo)therapy in locally advanced nonsmall cell lung cancer
por: Glatzer, Markus, et al.
Publicado: (2016)

Preoperative Radio(Chemo)Therapy in Breast Cancer: Time to Switch the Perspective?
por: Montero, Angel, et al.
Publicado: (2022)

Overcoming chemo/radio-resistance of pancreatic cancer by inhibiting STAT3 signaling
por: Wu, Xiaoqing, et al.
Publicado: (2016)

Overestimation of grey matter atrophy in glioblastoma patients following radio(chemo)therapy
por: Gommlich, A., et al.
Publicado: (2021)

Commentary: Immuno-chemo-radio-therapy before esophagectomy: Our next standard?
por: Ripley, R. Taylor
Publicado: (2022)

Influence of Interferon-Alpha Combined with Chemo (Radio) Therapy on Immunological Parameters in Pancreatic Adenocarcinoma
por: Karakhanova, Svetlana, et al.
Publicado: (2014)

Pathologic Assessment of Rectal Carcinoma after Neoadjuvant Radio(chemo)therapy: Prognostic Implications
por: Hav, Monirath, et al.
Publicado: (2015)

Stent patency in patients with distal malignant biliary obstruction receiving chemo(radio)therapy
por: Haal, Sylke, et al.
Publicado: (2017)

Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy
por: Hingorani, Dina V., et al.
Publicado: (2022)

Editorial: Combining chemo/radio therapy and immunotherapy for cancers—perfect mix of old and new
por: Slaney, Clare Y., et al.
Publicado: (2023)

Assessment of response to neoadjuvant radiochemotherapy with F-18 FLT and F-18 FDG PET/CT in patients with rectal cancer
por: Rendl, Gundula, et al.
Publicado: (2014)

Risk-adapted moderate hypofractionation of prostate cancer: A prospective analysis of acute toxicity, QOL and outcome in 221 patients
por: Schörghofer, Andreas, et al.
Publicado: (2019)

Targeting DNA Damage Response in the Radio(Chemo)therapy of Non-Small Cell Lung Cancer
por: Li, Ling, et al.
Publicado: (2016)

Association of mismatch repair status with survival and response to neoadjuvant chemo(radio)therapy in rectal cancer
por: Ye, Shu-Biao, et al.
Publicado: (2020)

Catechol enhances chemo- and radio-sensitivity by targeting AMPK/Hippo signaling in pancreatic cancer cells
por: Moon, Jeong Yong, et al.
Publicado: (2021)

IOERT versus external beam electrons for boost radiotherapy in stage I/II breast cancer: 10-year results of a phase III randomized study
por: Ciabattoni, Antonella, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vg92dg3ls3q57705t52bgscela